A new generation of checkpoint inhibitors is emerging, with some showing more promise than others. From recent TIGIT failures ...

Gilead Sciences, Inc. (NASDAQ ... showing that a combination of Trodelvy® and Keytruda® significantly improves progression-free survival compared to Keytruda and standard chemotherapy in ...

Gilead Sciences, Inc. (NASDAQ ... showing that a combination of Trodelvy® and Keytruda® significantly improves progression-free survival compared to Keytruda and standard chemotherapy in ...

Gilead Sciences, Inc. (GILD) and Kite to Present Breakthrough Cancer Therapy Data at 2025 ASCO and EHA A key highlight at ASCO will be late-breaking Phase 3 results from the ASCENT-04 trial, showing ...